Chronic hepatitis B surface antigen seroclearance-related immune factors

详细信息    查看全文

• 作者：Ting Yuan ; Yongfang Jiang ; Mei Li and Wei Li
• 刊名：Hepatology Research
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：47
• 期：1
• 页码：49-59
• 全文大小：347K
• ISSN：1872-034X

文摘

The ultimate aims of the treatment of hepatitis B virus infection are the loss of hepatitis B surface antigen (HBsAg) and body(Anti-HBs%29" title="Link to external resource: http://dict.cn/Hepatitis%20B%20surface%20antibody(Anti-HBs%29" target="_blank">hepatitis B surface antibody seroconversion. Unfortunately, these goals are rarely reached. Many factors are associated with HBsAg seroconversion, including genetic, immune, and viral factors. However, the mechanism of HBsAg seroclearance, and particularly the immune mechanism, is still difficult to elucidate. The immune factor interferon-α is currently the main antiviral therapy for chronic hepatitis B virus infection. However, a sustained shift from response of HBsAg to hepatitis B surface antibody seroconversion is rarely obtained. Recent studies have revealed that several of the newly identified immune factors are closely related to the removal of HBsAg. In this article, we review recent studies on these immune factors, their influence on hepatitis B progression, and HBsAg seroconversion.